Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

about

Osteoporosis and musculoskeletal complications related to therapy of breast cancer

P2860

Q57108686-C3FE4CB9-D52B-4A85-BBD3-E3D4959AA1C2

P2860

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

Item

http://www.wikidata.org/entity/Q38737784

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

@en

type

Item

label

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

@en

prefLabel

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

@en

P1476

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

@en

P2093

Gianluigi Lunardi

http://www.w3.org/2001/XMLSchema#string

Valentina Sini

http://www.w3.org/2001/XMLSchema#string

P2860

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.

A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum

P304

821-830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS-2017-0006

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stefania Gori

Paolo Marchetti

Andrea Botticelli

P577

2017-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28592202

http://www.w3.org/2001/XMLSchema#string

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

about

P2860

P2860

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698